Fatima Karzai

18PUBLICATIONS

123CO-AUTHORS

Molecular targetsPredictive and prognostic markersLiquid biopsiesRadiation therapyPsychophysiology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (18)

Sort by Publication Date:

|Jul 01, 2026

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

|Apr 11, 2026

EMBARK in biochemically recurrent prostate cancer: a journey for some but not most.

Melissa L Abel, Fatima Karzai, Ravi A Madan

|Mar 25, 2026

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Chennan Li, Ravi A Madan, Min-Jung Lee

|Feb 12, 2026

Integrative dual ctDNA 5mC/5hmC methylomics and clonal reconstruction infer tumor transcription and resistance phenotypes in metastatic prostate cancer.

Chennan Li, Anna Baj, Clara C Y Seo

|Jan 13, 2026

MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer.

Surendra Gulla, Tej Sharma, Ephraim Gardner

|Oct 23, 2025

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching

Pageof 3

Frequent Collaborators

11 joint publications

Ravi A Madan

James L Gulley

Adam Sowalsky

Jeffrey Schlom

Marijo Bilusic

Scott Wilkinson

David J VanderWeele

Johann S de Bono

William Figg

Nicolas T Terrigino

Frequent Collaborators

11 joint publications

Ravi A Madan

8 joint publications

James L Gulley

7 joint publications

Adam Sowalsky

5 joint publications

Jeffrey Schlom